share_log

Oppenheimer Upgrades AtriCure to Outperform, Announces $32 Price Target

Oppenheimer Upgrades AtriCure to Outperform, Announces $32 Price Target

奥本海默将AtriCure上调至跑赢大盘,宣布目标股价为32美元
Moomoo 24/7 ·  04/23 07:40

Oppenheimer analyst Suraj Kalia upgrades AtriCure (NASDAQ:ATRC) from Perform to Outperform and announces $32 price target.

奥本海默分析师苏拉杰·卡利亚将AtriCure(纳斯达克股票代码:ATRC)从表现上调至跑赢大盘,并宣布目标股价为32美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发